RT Journal
A1 Mitka M
T1 GHost busting
JF JAMA
JO JAMA
YR 2010
FD October 13
VO 304
IS 14
SP 1546
OP 1546
DO 10.1001/jama.2010.1416
UL http://dx.doi.org/10.1001/jama.2010.1416
AB 
Initially, Sen Max Baucus (D, Mont), Finance Committee chairman, and ranking member Sen Chuck Grassley (R, Iowa) warned Food and Drug Administration (FDA) Commissioner Margaret A. Hamburg, MD, in a July 12 letter that rosiglitazone was part of a ghostwriting program conducted by the drug's manufacturer, GlaxoSmithKline, and cited as evidence a paper that ultimately appeared in Circulation whose working title prior to publication was “Modifying Cardiovascular Risk in the Type 2 Diabetes Patient.” The AHA argued in an August 23 letter to Hamburg that Circulation had not published a review article with such a title and that Baucus and Grassley needed to provide a correction for the record (http://freepdfhosting.com/d3154f434e.pdf). The senators countered in a September 1 letter to Hamburg (http://freepdfhosting.com/b8f1a6c5a6.pdf) that Circulation did indeed publish the ghostwritten article but that its title had been changed to “Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus.”